CD274 and neoplasm: Similarly, a phase 1/1b trial of hypofractionated stereotactic body radiation therapy (SBRT) with single-dose anti-PD-L1 immunotherapy neoadjuvantly in head and neck tumours found clear signs of immunomodulation and antigen presentation, alongside the highest response rate yet observed in this tumour type 115.